Creative Planning Buys 10,245 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Creative Planning grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,525 shares of the company's stock after purchasing an additional 10,245 shares during the period. Creative Planning's holdings in Vaxcyte were worth $4,288,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in PCVX. Amalgamated Bank boosted its position in Vaxcyte by 4.2% during the second quarter. Amalgamated Bank now owns 3,759 shares of the company's stock valued at $284,000 after purchasing an additional 150 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Vaxcyte by 3.1% during the 2nd quarter. AQR Capital Management LLC now owns 10,860 shares of the company's stock worth $820,000 after purchasing an additional 328 shares in the last quarter. Xponance Inc. lifted its holdings in shares of Vaxcyte by 7.2% during the 2nd quarter. Xponance Inc. now owns 6,914 shares of the company's stock valued at $522,000 after buying an additional 465 shares during the last quarter. Fifth Third Bancorp bought a new stake in shares of Vaxcyte in the 2nd quarter valued at approximately $35,000. Finally, J.Safra Asset Management Corp increased its holdings in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after buying an additional 526 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of analyst reports. Needham & Company LLC lifted their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Leerink Partners boosted their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Finally, BTIG Research increased their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has an average rating of "Buy" and a consensus target price of $147.50.

Insider Transactions at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares of the company's stock, valued at $1,369,885.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 92,098 shares of company stock worth $9,937,773. Insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded up $0.62 during midday trading on Friday, hitting $112.94. The company's stock had a trading volume of 455,068 shares, compared to its average volume of 829,906. The stock's 50 day simple moving average is $105.41 and its 200 day simple moving average is $83.83. The stock has a market capitalization of $12.29 billion, a price-to-earnings ratio of -26.43 and a beta of 0.99. Vaxcyte, Inc. has a fifty-two week low of $45.61 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.04. During the same period last year, the business posted ($0.70) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.